137P Tislelizumab combined with chemotherapy as neoadjuvant therapy for stage IIIA-IIIB(N2) potentially resectable squamous non-small-cell lung cancer (TACT). (December 2022) - Shan, J.Z.; Liu, Z.; Du, C.; Hu, Y.; Ruan, L.; Teng, X.; Wang, L.; Du, M.; Tian, T.; Jiang, D.; Tu, Z.